Aileens Pharma S.r.l., a Milan, Italy-based developer of treatments to improve clinical outcomes in patients suffering from dermatological diseases, completed a €3M Series A financing.
The round was led by Panakes Partners, alongside Invitalia Ventures. As part of the financing, Panakes’ Barbara Castellano, Invitalia’ Svetlana Vashkel as well as industry expert Maurizio Comini (more than 30 years of expertise in the Dermatology Industry), joined the board of Aileens
The company intends to use the funds to accelerate the development of its platform of topical non-steroidal treatments for atopic dermatitis both in children and adults, as well as other types of dermatological disorders.
The round aims at completing the formulations, confirming the mechanism of action, carrying on the clinical developments of products treating three of the most diffused dermatological pathologies (Atopic Dermatitis, Seborrheic Dermatitis and Psoriasis), obtaining the CE mark and launching in European markets.
Led by founder and CEO Sonia Longo Sormani, who brings her background in the dermatology sector, having worked in Sinclair Pharmaceuticals, before creating her own company Claride Pharma, Aileens Pharma has developed innovative topical treatments dedicated to patients suffering from dermatological diseases, aiming to improving the patient’s clinical condition and quality of life using patented ingredients acting on the skin microbioma. The company partners with the Laboratory of Clinical Microbiology led by Prof. Roberto Di Marco from UNIMOL – Campobasso.